LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 18

Search options

  1. Article: Iron overload and malignancies in patients with haemoglobinopathies: A single center experience.

    Rigoli, Luciana / Petrungaro, Annamaria / Di Bella, Chiara / Caruso, Rosario

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

    2019  Volume 58, Issue 5, Page(s) 647–651

    Abstract: Thalassemias and sickle cell disease are a group of inherited blood disorders caused by alterations of the synthesis or of the structure of hemoglobin chains. It results in variable outcomes ranging from severe anemia to clinically asymptomatic ... ...

    Abstract Thalassemias and sickle cell disease are a group of inherited blood disorders caused by alterations of the synthesis or of the structure of hemoglobin chains. It results in variable outcomes ranging from severe anemia to clinically asymptomatic individuals. Hemolysis and transfusions therapies lead to iron overload and, thus, to an high production of reactive oxygen species (ROS). Recently, it was found an increasing frequency of tumors in patients with hemoglobinopathies and it was underlined the probable role of iron overload in the carcinogenesis. Here, we describe five patients with hemoglobinopathies affected by different types of cancers and we discuss the role of ROS in the carcinogenesis.
    MeSH term(s) Adult ; Female ; Hemolysis ; Humans ; Iron Overload/blood ; Iron Overload/etiology ; Male ; Neoplasms/blood ; Neoplasms/therapy ; Reactive Oxygen Species/blood ; Young Adult ; beta-Thalassemia/blood ; beta-Thalassemia/therapy
    Chemical Substances Reactive Oxygen Species
    Language English
    Publishing date 2019-09-05
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2019.08.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Anti-SARS-CoV-2 hyperimmune plasma workflow.

    Annamaria, Petrungaro / Eugenia, Quartarone / Paolo, Sciarrone

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

    2020  Volume 59, Issue 5, Page(s) 102850

    Abstract: Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus has become a Public Health Emergency of International Concern. Among the various treatment proposals for COVID-19 infection, passive immunotherapy using plasma from recovering patients - ...

    Abstract Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus has become a Public Health Emergency of International Concern. Among the various treatment proposals for COVID-19 infection, passive immunotherapy using plasma from recovering patients - "convalescent plasma" (CP)- could be a promising option in the treatment of SARS-CoV-2 infections. Immune (i.e. "convalescent") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. According to the World Health Organization (WHO), the use of plasma therapy is permitted when faced with «serious diseases for which there are no effective pharmacological treatments». Several clinical trials are underway to test the effectiveness of hyperimmune plasma at various stages of SARS-CoV2.The Food and Drug Administration (FDA), the U.S. regulatory authority, has approved the use of CP for compassionate use in the treatment of patients with a critical COVID-19 infection. Below are the general indications for drawing up clinical protocols for the integral management of "COVID-19-convalescent plasma" for which the validation and approval of the Ethics Committees is still necessary.
    MeSH term(s) COVID-19/epidemiology ; COVID-19/immunology ; COVID-19/therapy ; Disease Outbreaks ; Humans ; Immunization, Passive ; SARS-CoV-2/physiology ; Workflow
    Keywords covid19
    Language English
    Publishing date 2020-06-10
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2020.102850
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Anti-SARS-CoV-2 hyperimmune plasma workflow

    Annamaria, Petrungaro / Eugenia, Quartarone / Paolo, Sciarrone

    Transfusion and Apheresis Science

    2020  , Page(s) 102850

    Keywords Hematology ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2020.102850
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Anti-SARS-CoV-2 hyperimmune plasma workflow

    Annamaria, Petrungaro / Eugenia, Quartarone / Paolo, Sciarrone

    Transfus Apher Sci

    Abstract: Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus has become a Public Health Emergency of International Concern. Among the various treatment proposals for COVID-19 infection, passive immunotherapy using plasma from recovering patients - ...

    Abstract Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus has become a Public Health Emergency of International Concern. Among the various treatment proposals for COVID-19 infection, passive immunotherapy using plasma from recovering patients - "convalescent plasma" (CP)- could be a promising option in the treatment of SARS-CoV-2 infections. Immune (i.e. "convalescent") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. According to the World Health Organization (WHO), the use of plasma therapy is permitted when faced with «serious diseases for which there are no effective pharmacological treatments¼. Several clinical trials are underway to test the effectiveness of hyperimmune plasma at various stages of SARS-CoV2.The Food and Drug Administration (FDA), the U.S. regulatory authority, has approved the use of CP for compassionate use in the treatment of patients with a critical COVID-19 infection. Below are the general indications for drawing up clinical protocols for the integral management of "COVID-19-convalescent plasma" for which the validation and approval of the Ethics Committees is still necessary.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #592496
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Pomalidomide in multiple myeloma.

    Uccello, Giuseppina / Petrungaro, Annamaria / Mazzone, Carla / Recchia, Anna Grazia / Greco, Rosa / Mendicino, Francesco / Lucia, Eugenio / Vigna, Ernesto / Morabito, Fortunato / Gentile, Massimo

    Expert opinion on pharmacotherapy

    2017  Volume 18, Issue 2, Page(s) 133–137

    Language English
    Publishing date 2017
    Publishing country England
    Document type Journal Article
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2016.1274973
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies.

    Vigna, Ernesto / Petrungaro, Annamaria / Perri, Anna / Terzi, Dario / Recchia, Anna Grazia / Mendicino, Francesco / La Russa, Antonella / Bossio, Sabrina / De Stefano, Laura / Zinno, Francesco / Bonofiglio, Renzo / Morabito, Fortunato / Gentile, Massimo

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

    2018  Volume 57, Issue 2, Page(s) 247–249

    Abstract: Thrombotic thrombocytopenic purpura (TTP) is a rare microangiopathic hemolytic anemia (MAHA) defined by mechanical hemolytic anemia, severe thrombocytopenia, and systemic visceral ischemia due to systemic platelet-rich microthrombi. Forty percent of ... ...

    Abstract Thrombotic thrombocytopenic purpura (TTP) is a rare microangiopathic hemolytic anemia (MAHA) defined by mechanical hemolytic anemia, severe thrombocytopenia, and systemic visceral ischemia due to systemic platelet-rich microthrombi. Forty percent of patients with autoimmune TTP experience one or multiple relapses. Patients with refractory TTP are currently managed by corticosteroids, twice-daily PEX, and the anti-CD20 monoclonal antibody rituximab. Herein, we report two cases of severe TTP, refractory to those standard agents. On the basis of the fact that in cases of severe TTP the classical complement pathway is activated, and that the alternative pathway is also involved, both patients underwent eculizumab (anti-C5 monoclonal antibody) therapy. We observed prompt hematological and organ system responses to the eculizumab and the recovery of plasma ADAMTS-13 activity in both cases. Moreover, the fact that both patients discontinued eculizumab, maintaining the response, emphasizes the possibility of its usefulness for limited treatment periods. In conclusion, the diagnostic and therapeutic algorithm in TTP appears complicated by increasing evidence of complement involvement and the eculizumab seems to be a potential agent for refractory patients.
    MeSH term(s) ADAMTS13 Protein/metabolism ; Adult ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Humans ; Male ; Middle Aged ; Purpura, Thrombotic Thrombocytopenic/drug therapy
    Chemical Substances Antibodies, Monoclonal, Humanized ; eculizumab (A3ULP0F556) ; ADAMTS13 Protein (EC 3.4.24.87) ; ADAMTS13 protein, human (EC 3.4.24.87)
    Language English
    Publishing date 2018-03-15
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2018.03.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia.

    Gangemi, Sebastiano / Allegra, Alessandro / Profita, Mirella / Saitta, Salvatore / Gerace, Demetrio / Bonanno, Anna / Alonci, Andrea / Petrungaro, Annamaria / Russo, Sabina / Musolino, Caterina

    Cancer investigation

    2013  Volume 31, Issue 3, Page(s) 212–213

    MeSH term(s) Aged ; Female ; Humans ; Interleukin-33 ; Interleukins/blood ; Interleukins/physiology ; Male ; Middle Aged ; Polycythemia Vera/immunology ; Th2 Cells/immunology ; Thrombocythemia, Essential/immunology
    Chemical Substances IL33 protein, human ; Interleukin-33 ; Interleukins
    Language English
    Publishing date 2013-03
    Publishing country England
    Document type Journal Article
    ZDB-ID 604942-4
    ISSN 1532-4192 ; 0735-7907
    ISSN (online) 1532-4192
    ISSN 0735-7907
    DOI 10.3109/07357907.2013.764566
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Venetoclax for the treatment of chronic lymphocytic leukemia.

    Gentile, Massimo / Petrungaro, Annamaria / Uccello, Giuseppina / Vigna, Ernesto / Recchia, Anna Grazia / Caruso, Nadia / Bossio, Sabrina / De Stefano, Laura / Palummo, Angela / Storino, Francesca / Martino, Massimo / Morabito, Fortunato

    Expert opinion on investigational drugs

    2017  Volume 26, Issue 11, Page(s) 1307–1316

    Abstract: Introduction: Venetoclax, an orally bioavailable inhibitor of BCL-2, was approved in 2016 by the United States Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) patients with 17p deletion [del(17p)], who have ... ...

    Abstract Introduction: Venetoclax, an orally bioavailable inhibitor of BCL-2, was approved in 2016 by the United States Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) patients with 17p deletion [del(17p)], who have received at least one prior therapy. Areas covered: We focus on the mechanism of action of venetoclax and on the clinical trial data that led to the approval of venetoclax for CLL patients. We also review the studies in which this drug has being explored in combination with other anti-CLL drugs. Expert opinion: Data from early clinical trials have shown that venetoclax, as a single agent, is highly effective for relapsed/refractory CLL patients, including those cases with high-risk features. Furthermore, venetoclax seems to be an appropriate option for patients who progress on B-cell receptor (BCR) pathway kinase inhibitors. Venetoclax is also safe, with the most common serious adverse events being neutropenia. The risk of tumor lysis syndrome (TLS) can be reduced by a slow dose ramp-up, careful monitoring, and adequate prophylaxis. Ongoing trials will further clarify the safety and efficacy of venetoclax in combination with other drugs in both relapsed/refractory and untreated CLL patients.
    MeSH term(s) Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Dose-Response Relationship, Drug ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Neutropenia/chemically induced ; Neutropenia/epidemiology ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Sulfonamides/pharmacology ; Tumor Lysis Syndrome/prevention & control
    Chemical Substances Antineoplastic Agents ; Bridged Bicyclo Compounds, Heterocyclic ; Sulfonamides ; venetoclax (N54AIC43PW)
    Language English
    Publishing date 2017-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1080/13543784.2017.1386173
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.

    Petrungaro, Annamaria / Gentile, Massimo / Mazzone, Carla / Greco, Rosa / Uccello, Giuseppina / Recchia, Anna Grazia / De Stefano, Laura / Bossio, Sabrina / Palummo, Angela / Morelli, Rosellina / Musolino, Caterina / Morabito, Fortunato / Vigna, Ernesto

    Chemotherapy

    2017  Volume 62, Issue 6, Page(s) 353–356

    Abstract: We describe the case of a patient with Philadelphia-positive acute lymphoblastic leukemia treated with dasatinib plus steroids as first-line therapy, who achieved a major molecular response (MMR) before undergoing matched, unrelated donor allogeneic stem ...

    Abstract We describe the case of a patient with Philadelphia-positive acute lymphoblastic leukemia treated with dasatinib plus steroids as first-line therapy, who achieved a major molecular response (MMR) before undergoing matched, unrelated donor allogeneic stem cell transplant. Eleven months after the transplant, she experienced molecular relapse. Mutational screening showed negativity for the T315I mutation, The patient underwent a salvage chemotherapy regimen with clofarabine + cyclophosphamide + steroids and ponatinib (clofarabine 70 mg i.v., days 1-5, cyclophosphamide 700 mg i.v., days 1-5, and ponatinib 45 mg p.o., daily starting at day 15). We observed a rapid decrease in minimal residual disease on molecular assessment with an MMR of P190-BCR-ABL/ABL = 0.01% confirmed by bone marrow revaluations at days +23, +59, +108, and +191 after the first day of salvage chemotherapy. After starting ponatinib, the patient experienced skin graft-versus-host disease, suggesting that the efficacy of ponatinib could be related not only to the direct antileukemic effect but also to its ability to promote an indirect graft-versus-leukemia effect. Ponatinib treatment was well tolerated and considered safe with easily manageable side effects.
    Language English
    Publishing date 2017-08-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 6708-8
    ISSN 1421-9794 ; 0009-3157
    ISSN (online) 1421-9794
    ISSN 0009-3157
    DOI 10.1159/000477714
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uf I Zs.174: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review).

    Allegra, Alessandro / Alonci, Andrea / Campo, Salvatore / Penna, Giuseppa / Petrungaro, Annamaria / Gerace, Demetrio / Musolino, Caterina

    International journal of oncology

    2012  Volume 41, Issue 6, Page(s) 1897–1912

    Abstract: MicroRNAs (miRNAs) are small non-coding, endogenous, single-stranded RNAs. MiRNAs have been implicated in different areas such as the immune response, neural development, DNA repair, apoptosis, oxidative stress response and cancer. ...

    Abstract MicroRNAs (miRNAs) are small non-coding, endogenous, single-stranded RNAs. MiRNAs have been implicated in different areas such as the immune response, neural development, DNA repair, apoptosis, oxidative stress response and cancer. However, while the majority of miRNAs are found intracellularly, a significant number of miRNAs have been observed outside of cells, including various body fluids. Circulating miRNAs function as 'extracellular communication RNAs' that play an important role in cell proliferation and differentiation. MiRNA regulation is essential to many cellular processes, and escape from this regulatory network seems to be a common characteristic of several disease processes and malignant transformation. The interest in circulating miRNAs reflects in fact their central role in regulation of gene expression and the implication of miRNA-specific aberrant expression in the pathogenesis of cancer, cardiac, metabolic, neurologic, immune-related diseases as well as others. In our review we aimed to summarize the data related to the action of cellular miRNAs on the onset of various diseases, thus bringing together some of the latest information available on the role of circulating miRNAs. Additionally, the role of circulating miRNAs could be particularly relevant in the context of neoplastic diseases. At least 79 miRNAs have been reported as plasma or serum miRNA biomarkers of solid and hematologic tumors. Circulating miRNA profiling could improve the diagnosis of cancer, and could predict outcome for cancer patients, while the profiling of alterations in circulating miRNA that may signal a predisposition to cancer, could also be a therapeutic target in these patients.
    MeSH term(s) Autoimmune Diseases/diagnosis ; Autoimmune Diseases/genetics ; Biomarkers, Tumor/blood ; Cell Communication ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Inflammation/diagnosis ; Inflammation/genetics ; Metabolic Diseases/diagnosis ; Metabolic Diseases/genetics ; MicroRNAs/blood ; Neoplasms/diagnosis ; Neoplasms/genetics ; Neoplasms/therapy ; Prognosis
    Chemical Substances Biomarkers, Tumor ; MicroRNAs
    Language English
    Publishing date 2012-12
    Publishing country Greece
    Document type Journal Article ; Review
    ZDB-ID 1154403-x
    ISSN 1791-2423 ; 1019-6439
    ISSN (online) 1791-2423
    ISSN 1019-6439
    DOI 10.3892/ijo.2012.1647
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3690: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top